Ticagrelor indications and usage: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
====Acute Coronary Syndromes==== | ====Acute Coronary Syndromes==== | ||
BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with [[acute coronary syndrome]] (ACS) ([[unstable angina]], non-ST elevation [[myocardial infarction]], or ST elevation [[myocardial infarction]]). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, [[myocardial infarction]] or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent [[thrombosis]] | BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with [[acute coronary syndrome]] (ACS) ([[unstable angina]], non-ST elevation [[myocardial infarction]], or ST elevation [[myocardial infarction]]). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, [[myocardial infarction]] or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent [[thrombosis]] ''[see [[Ticagrelor clinical studies|Clinical Studies]]]''. | ||
BRILINTA has been studied in ACS in combination with [[aspirin]]. Maintenance doses of [[aspirin]] above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of [[aspirin]] above 100 mg daily | BRILINTA has been studied in ACS in combination with [[aspirin]]. Maintenance doses of [[aspirin]] above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of [[aspirin]] above 100 mg daily ''[see [[Ticagrelor warnings and precautions|Warnings and Precautions]] and [[Ticagrelor clinical studies|Clinical Studies]]]''.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 22:35, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Indications and Usage
Acute Coronary Syndromes
BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis [see Clinical Studies].
BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily [see Warnings and Precautions and Clinical Studies].[1]